Table 3 Results of the base case cost-effectiveness analysis
Components | Group A Do Nothing | Group B Supp only | Group C Screen (B12) & Supp | Group D Screen (Folate and B12) & Supp (Folate Deficient) |
|---|---|---|---|---|
Expected medical costs of intervention | US$140.59 | US$377.84 | US$388.33 | US$224.77 |
Expected medical costs of stroke | US$138.19 | US$108.08 | US$108.08 | US$118.38 |
Total medical costs | US$278.78 | US$485.92 | US$496.40 | US$343.15 |
Total expected QALYS | 3.8699 | 3.8742 | 3.8766 | 3.8731 |
Incremental cost vs. A | 听 | 207.13 | 217.62 | 64.37 |
Incremental QALYs vs. A | 听 | 0.0043 | 0.0067 | 0.0032 |
ICER with respect to Group A | 听 | 47,967.75 | 32,614.71 | 20,286.94 |